Routine blood tests |
|
|
|
|
White blood cell count (×109/L), median (IQR) |
4.9
(3.0–10.5) |
4.9 (3.0–10.5) |
9.2 (5.9–14.2) |
.521 |
Red blood cell count (×1012/L), mean ± SD |
3.6 ± 0.8 |
3.6 ± 0.8 |
3.5 ± 1.0 |
.469 |
Hemoglobin (g/L), mean ± SD |
108.7 ± 26.0 |
108.7 ± 26.0 |
105.3 ± 28.0 |
.650 |
Platelet count (×109/L), median (IQR) |
183.0
(65.5–284.0) |
183.0 (65.5–284.0) |
183.0 (106.0–262.3) |
.654 |
Liver function tests |
|
|
|
|
Alanine aminotransferase (U/L), median (IQR) |
21.0 (11.0–46.5) |
21.0
(11.0–46.5) |
22.0 (13.0–44.8) |
.898 |
Aspartate transaminase (U/L), median (IQR) |
30.0 (20.5–53.0) |
30.0
(20.5–53.0) |
30.0 (18.0–54.7) |
.466 |
Albumin (g/L), mean ± SD |
35.1 ± 8.7 |
35.1 ± 8.7 |
35.6 ± 7.3 |
.361 |
Globulin (g/L), mean ± SD |
30.4 ± 6.4 |
30.4 ± 6.4 |
30.1 ± 8.3 |
.526 |
Total bilirubin (μmol/L), median (IQR) |
9.4 (4.9–21.0) |
9.4
(4.9–21.0) |
11.9 (7.4–19.6) |
.360 |
Direct bilirubin (μmol/L), median (IQR) |
4.7 (2.4–9.7) |
4.7
(2.4–9.7) |
5.4 (3.2–9.4) |
.468 |
Alkaline phosphatase (U/L), median (IQR) |
104.0 (76.0–129.5) |
104.0
(76.0–129.5) |
82.0 (61–116.8) |
.017* |
γ-Glutamyl transpeptidase (U/L), median (IQR) |
55.5 (19.3–125.3) |
55.5 (19.3–125.3) |
41 (22.0–83.8) |
.272 |
Serum lipids |
|
|
|
|
Total cholesterol (mmol/L), mean ± SD |
3.4 ± 1.2 |
3.4 ± 1.2 |
3.4 ±1.4 |
.462 |
Triglyceride (mmol/L), median (IQR) |
1.7 (1.0–2.7) |
1.7 (1.0–2.7) |
1.3 (0.9–1.9) |
.332 |
Low density lipoprotein (mmol/L), median (IQR) |
2.0 (1.5–2.5) |
2.0
(1.5–2.5) |
1.8 (1.3–2.5) |
.326 |
Electrolyte indices |
|
|
|
|
Potassium (mmol/L), mean ± SD |
4.3 ± 0.7 |
4.3 ± 0.7 |
4.1 ± 0.7 |
.757 |
Sodium (mmol/L), mean ± SD |
140.4 ± 5.3 |
140.4 ± 5.3 |
138.5 ± 6.8 |
.234 |
Calcium (mmol/L), mean ± SD |
2.2 ± 0.2 |
2.2 ± 0.2 |
2.1 ± 0.2 |
.345 |
Corrected calcium (mmol/L), mean ± SD |
2.4 ± 0.1 |
2.4 ± 0.1 |
2.4 ±
0.2 |
.955 |
Renal function tests |
|
|
|
|
Urea nitrogen (mmol/L), median (IQR) |
5.8 (3.3–10.3) |
5.8 (3.3–10.3) |
5.8 (4.2–9.6) |
.370 |
Creatinine (μmol/L), median (IQR) |
75.0 (56.0–119.8) |
75.0
(56.0–119.8) |
70.5 (57.0–109.8) |
.680 |
Uric acid (μmol/L), median (IQR) |
231.4 (174.0–512.3) |
231.4
(174.0–512.3) |
273.5 (190.4–373.2) |
.416 |
Bicarbonate radical (mmol/L), median (IQR) |
21.6 (19.5–24.5) |
21.6
(19.5–24.5) |
23.4 (20.3–25.2) |
.312 |
Estimated glomerular filtration
rate (ml/min/1.73 m2), median (IQR) |
99.0
(50.5–112.6) |
99.0 (50.5–112.6) |
93.6 (58.1–109.4) |
.733 |
Infection indices |
|
|
|
|
High-sensitivity C-reactive protein (mg/L), median (IQR) |
19.9
(3.8–133.3) |
19.9 (3.8–133.3) |
47.2 (14.1–121.3) |
.261 |
Erythrocyte sedimentation rate (mm/h), median (IQR) |
79 (18–89) |
79
(18–89) |
31.0 (10.3–65.8) |
.401 |
Procalcitonin (ng/mL), median (IQR) |
0.2 (0.1–2.0) |
0.2 (0.1–2.0) |
0.4 (0.1–2.7) |
.164 |
Coagulation function tests |
|
|
|
|
Prothrombin time (s), median (IQR) |
14.1 (13.2–15.1) |
14.1
(13.2–15.1) |
14.8 (13.8–16.2) |
.053* |
Fibrinogen (g/L), median (IQR) |
4.4 (3.0–5.3) |
4.4 (3.0–5.3) |
4.4
(3.2–5.7) |
.621 |
Activated partial thromboplastin time (s), median (IQR) |
36.8
(35.2–42.5) |
36.8 (35.2–42.5) |
41.2 (36.6–46.9) |
.072* |
D-dimer (μg/mL), median (IQR) |
3.5 (2.5–7.4) |
3.5 (2.5–7.4) |
2.3
(1.0–5.8) |
.145 |
Therapeutic regimens |
|
|
|
|
Loading dose of tigecycline use, n (%) |
|
|
|
|
≥100 mg |
10 (47.6) |
10 (47.6) |
1857 (49.9) |
.833 |
≤50 mg or none |
11 (52.4) |
11 (52.4) |
1863 (50.1) |
|
Maintenance dose of tigecycline, n (%) |
|
|
|
|
≥100 mg q12h |
2 (9.5) |
2 (9.5) |
315 (8.5) |
.862 |
≤50 mg q12h |
19 (90.5) |
19 (90.5) |
3405 (91.5) |
|
Duration of tigecycline use, median (IQR) |
10.0 (6.0–12.5) |
10.0
(6.0–12.5) |
8 (6–13) |
.753 |
Total dose of tigecycline (mg), median (IQR) |
1100 (750–1450) |
1100
(750–1450) |
900 (700–1400) |
.492 |